Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms
Status:
Completed
Trial end date:
2019-08-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended
Phase 2 dose of TAB08 when administered intravenously (i.v.) to patients with advanced solid
malignancies.